TNXP (Tonix Pharmaceuticals Holding) Tariff Resilience Score: 7/10 (As of Jul. 09, 2026)


TNXP Tonix Pharmaceuticals Holding Corp TNXP
39 GF Score
Price $13.03
GF Value $1.75
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Tonix Pharmaceuticals Holding Tariff Resilience Score?

Tonix Pharmaceuticals Holding TNXP +2.04% 39 Tariff Resilience Score is 7 as of Jul. 09, 2026. GuruFocus rates TNXP with a GF Score™ of 39/100 and a GF Value™ of $1.75 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,368 Biotechnology companies, Tonix Pharmaceuticals Holding ranks better than 90.35% on this metric.

Tonix Pharmaceuticals Holding has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Tonix Pharmaceuticals Holding has Tonix Pharmaceuticals has a diversified supply chain with significant domestic production, reducing tariff exposure. The pharmaceutical industry often benefits from exemptions, and the company has shown resilience to past tariff changes through strategic sourcing.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Tonix Pharmaceuticals Holding might have Highly Resilient.

Tonix Pharmaceuticals Holding  (NAS:TNXP) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Tonix Pharmaceuticals Holding Tariff Resilience Score Related Terms

TNXP vs ALEC, IMUX, WHWK: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Tonix Pharmaceuticals Holding's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tonix Pharmaceuticals Holding Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tonix Pharmaceuticals Holding's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Tonix Pharmaceuticals Holding's Tariff Resilience Score falls into.


TNXP
39GF Score
Tonix Pharmaceuticals Holding Corp TNXP
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Tonix Pharmaceuticals Holding (TNXP) has a Tariff Resilience Score of 7 as of Jul. 09, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Tonix Pharmaceuticals Holding ranks #132 out of 1368 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Tonix Pharmaceuticals Holding's Tariff Resilience Score too high?
Tonix Pharmaceuticals Holding's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Tonix Pharmaceuticals Holding's value of 7 is 75% above this industry median. Based on the distribution chart, Tonix Pharmaceuticals Holding ranks #132 out of 1368 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Tonix Pharmaceuticals Holding has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tonix Pharmaceuticals Holding's Tariff Resilience Score compare to ALEC and IMUX?
According to the Biotechnology industry distribution chart, Tonix Pharmaceuticals Holding ranks #132 out of 1368 companies for Tariff Resilience Score. This places Tonix Pharmaceuticals Holding in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Tonix Pharmaceuticals Holding's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,368 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tonix Pharmaceuticals Holding's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tonix Pharmaceuticals Holding's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tonix Pharmaceuticals Holding stock overvalued right now?
Based on GuruFocus' analysis, Tonix Pharmaceuticals Holding (TNXP) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.75, compared to a current price of $13.03 — trading 644.6% above its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Tonix Pharmaceuticals Holding's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Tonix Pharmaceuticals Holding (TNXP), the current Tariff Resilience Score is 7 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tonix Pharmaceuticals Holding (TNXP) Overvalued in 2026?

Based on GuruFocus' analysis, Tonix Pharmaceuticals Holding stock appears to be overvalued. The current stock price of $13.03 is trading 644.6% above its estimated GF Value™ of $1.75. GuruFocus considers Tonix Pharmaceuticals Holding to be Significantly Overvalued.

Key valuation signals for TNXP:

  • Tariff Resilience Score: 7
  • GF Value™: $1.75 vs. price of $13.03 (644.6% above fair value)
  • GF Score™: 39/100 with 2 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1368)

No single metric tells the full story. See the TNXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tonix Pharmaceuticals Holding Business Description

Other Exchanges TPM0:Germany
Address 200 Connell Drive, Suite 3100, Berkeley Heights, NJ, USA, 07928
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
39GF Score

Get the complete analysis for TNXP

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.03
Price
$1.75
GF Value